Don't Judge Cardinal Health on Technicals Alone - Check Its Fundamentals!

By Harris Dyer • Friday, April 21 09:46 • Permanent Link

Cardinal Health logged a 0.1% change during today's morning session, and is now trading at a price of $80.2 per share. The S&P 500 index moved 0.0%. CAH's trading volume is 82,647 compared to the stock's average volume of 2,507,945.

Cardinal Health trades -5.87% away from its average analyst target price of $85.21 per share. The 14 analysts following the stock have set target prices ranging from $76.0 to $97.0, and on average have given Cardinal Health a rating of hold.

Anyone interested in buying CAH should be aware of the facts below:

Cardinal Health's current price is 170.9% above its Graham number of $29.61, which implies that at its current valuation it does not offer a margin of safety
Cardinal Health has moved 30.1% over the last year, and the S&P 500 logged a change of -3.3%
Based on its trailing earnings per share of -4.56, Cardinal Health has a trailing 12 month Price to Earnings (P/E) ratio of -17.6 while the S&P 500 average is 15.97
CAH has a forward P/E ratio of 12.7 based on its forward 12 month price to earnings (EPS) of $6.34 per share
The company has a price to earnings growth (PEG) ratio of 1.24 — a number near or below 1 signifying that Cardinal Health is fairly valued compared to its estimated growth potential
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.
Based in Dublin, the company has 45,570 full time employees and a market cap of $20,951,711,744. Cardinal Health currently returns an annual dividend yield of 2.5%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.